Exenatide

Exenatide is a synthetic analog of exendin-4, a 39-amino-acid peptide originally isolated from the salivary secretions of the Gila monster (Heloderma suspectum). It shares 53% amino acid sequence homology with native human glucagon-like peptide-1 (GLP-1) and functions as a full agonist at the GLP-1 receptor, a G protein-coupled receptor expressed on pancreatic beta cells, alpha cells, gastrointestinal tract, hypothalamus, heart, and kidneys.

In patients with type 2 diabetes, activation of the GLP-1 receptor by exenatide produces several coordinated metabolic effects. Insulin secretion is stimulated in a strictly glucose-dependent manner: exenatide augments pancreatic beta-cell secretory response only when plasma glucose is elevated, substantially limiting hypoglycemia risk in the fasting state. Concurrently, exenatide suppresses inappropriately elevated glucagon secretion from pancreatic alpha-cells, reducing hepatic glucose output.

A critical pharmacological advantage over native GLP-1 is resistance to degradation by dipeptidyl peptidase-IV (DPP-4), the enzyme that inactivates endogenous GLP-1 within approximately two minutes of secretion. This structural resistance confers a plasma half-life of roughly 2.4 hours for the immediate-release formulation, enabling twice-daily subcutaneous administration. The extended-release formulation uses biodegradable poly-(D,L-lactide-co-glycolide) microspheres to sustain plasma concentrations throughout the week.

• Exenatide slows gastric emptying, attenuating the postprandial rise in blood glucose and promoting early satiety. • Reduced caloric intake and decreased food-reward signaling in the central nervous system contribute to the body weight loss consistently observed in clinical trials. • Preclinical data suggest trophic effects on pancreatic beta cells, including stimulation of neogenesis and inhibition of apoptosis; clinical significance in humans remains under investigation.

Pivotal efficacy for exenatide twice daily (Byetta) was established in three Phase 3 randomized, placebo-controlled, 30-week trials enrolling patients on background metformin, sulfonylurea, or the combination. Across these trials, 10 mcg twice daily reduced mean HbA1c by 0.8 to 1.7 percentage points compared with placebo, with concomitant body weight reductions of approximately 1.6 to 2.7 kg at 30 weeks. Glycemic improvements were sustained through 82-week and 3-year open-label extensions.

The DURATION clinical trial program (DURATION-1 through DURATION-5) evaluated exenatide 2 mg once weekly against multiple active comparators — including exenatide twice daily, sitagliptin, pioglitazone, and insulin glargine — in 24- to 30-week randomized trials. HbA1c reductions ranged from 1.3 to 1.9 percentage points, with 58 to 77 percent of patients achieving targets below 7.0 percent. Body weight decreased 2.0 to 3.7 kg. In DURATION-1, weight loss with once-weekly exenatide was 3.7 kg at 30 weeks, and once-weekly was superior to twice-daily on the primary HbA1c endpoint. In a 52-week randomized trial, once-weekly exenatide reduced HbA1c by 1.3 percentage points, fasting plasma glucose by 36.3 mg/dL, and systolic blood pressure by 3.6 mmHg, with 68 percent achieving HbA1c below 7.0 percent.

Cardiovascular safety was assessed in the EXSCEL trial (NCT01144338), a randomized, double-blind, placebo-controlled cardiovascular outcomes trial enrolling 14,752 patients with type 2 diabetes across 35 countries, with a median follow-up of 3.2 years; 73.1 percent had pre-existing cardiovascular disease. The primary composite endpoint of cardiovascular death, myocardial infarction, or stroke occurred in 11.4 percent of the exenatide group versus 12.2 percent of placebo (p less than 0.001 for noninferiority; p = 0.06 for superiority). A nominal 14 percent relative reduction in all-cause mortality was observed (6.9 percent vs 7.9 percent; HR 0.86, 95% CI 0.77 to 0.98). EXSCEL established cardiovascular noninferiority for once-weekly exenatide; superiority was not demonstrated. Pediatric efficacy was established in the Phase 3 BCB114 trial (n=82, ages 10 to 17 years, 24-week placebo-controlled period), which demonstrated significantly greater mean HbA1c reduction with exenatide extended-release versus placebo.

Typical dosage: 5–10 mcg (Byetta) or 2 mg (Bydureon/Bydureon BCise) (Twice daily (Byetta) or once weekly (Bydureon)).

Byetta (exenatide injection, immediate release): Initiate at 5 mcg administered subcutaneously twice daily, within 60 minutes before the morning and evening meals (or before the two main meals of the day, at least 6 hours apart). After a minimum of one month, the dose may be increased to 10 mcg twice daily based on clinical response and tolerability; 10 mcg twice daily is the maximum recommended dose. Doses should not be administered after meals. Suitable injection sites include the thigh, abdomen, or upper arm; sites should be rotated.

Bydureon and Bydureon BCise (exenatide extended-release): Administer 2 mg subcutaneously once weekly at any time of day, with or without meals. No dose titration is required. The Bydureon BCise autoinjector pen delivers a single 2 mg dose per injection.

Renal impairment: Use with caution in patients with moderate renal impairment (creatinine clearance 30 to 50 mL/min); dose escalation should proceed conservatively. Exenatide is not recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or end-stage renal disease.

Concomitant sulfonylurea: Consider reducing the sulfonylurea dose when initiating exenatide to reduce hypoglycemia risk. No dose adjustment is generally required for metformin or thiazolidinediones.

Pediatric use (Bydureon BCise only): 2 mg once weekly in patients 10 years and older with type 2 diabetes.

This information is provided for educational and reference purposes only and does not constitute medical advice. Dosing decisions should be made by a licensed healthcare provider based on individual patient assessment and current FDA-approved prescribing information.

Exenatide is approved as an adjunct to diet and exercise in combination with multiple antidiabetic regimens. Both the immediate-release and extended-release formulations have been studied and approved in combination with metformin, sulfonylureas, and thiazolidinediones individually or in combination. The extended-release formulation (Bydureon) is additionally approved in combination with basal insulin glargine, with or without metformin and/or a thiazolidinedione.

When co-administered with sulfonylureas, reduction of the sulfonylurea dose is recommended at initiation to reduce hypoglycemia risk, as incidence rises to 12 to 20 percent of patients in this setting compared with 1 to 8 percent without a sulfonylurea. Combination with metformin does not substantially increase hypoglycemia risk. Exenatide is not approved for use with rapid-acting or short-acting prandial insulin analogs. Co-administration with a second GLP-1 receptor agonist is not recommended. Simultaneous use with a DPP-4 inhibitor (gliptin class) provides little additional glycemic benefit and is generally avoided in clinical practice.

A pharmacokinetic consideration: exenatide slows gastric emptying and can delay absorption of orally co-administered drugs. Oral medications with narrow therapeutic windows or requiring rapid gastrointestinal absorption — such as antibiotics or oral hormonal contraceptives — should be taken at least one hour before exenatide injection to prevent clinically significant absorption delays. Digoxin and lisinopril interactions have not been considered clinically significant in available data. (Note: combination experience with newer agents such as SGLT-2 inhibitors is anecdotal in nature and reflects off-label clinical practice rather than FDA-approved combination labeling.)

Exenatide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Nausea, vomiting, diarrhea, injection site reactions, hypoglycemia (when co-administered with sulfonylureas), rare acute pancreatitis, rare acute kidney injury

The most frequently reported adverse effect across exenatide clinical trials is nausea, with an incidence of approximately 36.9 percent in long-term studies; in the DURATION-1 once-weekly trial, nausea occurred in 26.4 percent of patients. Nausea is generally mild to moderate in severity, typically diminishes over the first 8 weeks of treatment, and is less prevalent with the once-weekly extended-release formulation compared with twice-daily dosing. Additional gastrointestinal adverse events include vomiting, diarrhea, and constipation. Injection site reactions — bruising, pruritus, and subcutaneous nodules — have been reported, particularly with the extended-release microsphere formulation.

The intrinsic risk of hypoglycemia is low when exenatide is used without insulin secretagogues. Co-administration with sulfonylureas increases hypoglycemia incidence to approximately 12 to 20 percent in clinical trials; sulfonylurea dose reduction at initiation is recommended.

Postmarketing surveillance has identified rare but serious cases of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Exenatide should be discontinued if pancreatitis is suspected and not restarted if the diagnosis is confirmed. Patients with a history of pancreatitis should use alternative agents where possible.

Rare cases of acute kidney injury have been reported, predominantly in the context of volume depletion from nausea, vomiting, and diarrhea. Exenatide is not recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/min).

Bydureon and Bydureon BCise (extended-release) carry a black-box warning for risk of thyroid C-cell tumors based on dose-dependent increases in thyroid C-cell adenomas and carcinomas in rodent studies at clinically relevant exposures. Relevance to humans has not been established; however, Bydureon is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. This black-box warning does not apply to Byetta (immediate-release exenatide). A small proportion of patients develop anti-exenatide antibodies; high-titer antibodies have been associated with attenuated glycemic response in a subset of patients.